ANTHEM vs BETA: Stock Comparison
ANTHEM BIOSCIENCES is the larger company by market capitalisation. ANTHEM BIOSCIENCES shows a higher ROE, a higher dividend yield and faster revenue growth, while BETA DRUGS shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ANTHEM leads 11; BETA leads 2 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ANTHEM | BETA |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Biotechnology | — |
Price
| Metric | ANTHEM | BETA |
|---|---|---|
| Live Price | ₹917.55 | ₹2,079 |
| Day Change | 1% | 0.68% |
| Volume | 1.73 L | 4,664 |
| 52-Week High | ₹977.55 | ₹2,807.9 |
| 52-Week Low | ₹579.15 | ₹990.1 |
| Distance from 52W High | -6.14% | -25.96% |
Valuation
| Metric | ANTHEM | BETA |
|---|---|---|
| Market Cap | ₹51,941 Cr | ₹2,303 Cr |
| P/E Ratio | 89.17x | 50.32x |
| P/B Ratio | 16.88x | 8.53x |
| EPS | ₹10.09 | ₹5.35 |
| Book Value | ₹54.17 | ₹220.79 |
| Dividend Yield | 0.21% | 0% |
Growth
| Metric | ANTHEM | BETA |
|---|---|---|
| Revenue Growth (TTM YoY) | 26.4% | 0% |
| EPS Growth (TTM YoY) | 127.2% | 0% |
| Qtr Sales Growth | -8.22% | -55.53% |
| Qtr Profit Growth | -14.95% | -64.01% |
Profitability & Leverage
| Metric | ANTHEM | BETA |
|---|---|---|
| ROE | 21.06% | 9.58% |
| ROCE | 22.79% | 14.63% |
| Net Margin | 26.05% | 10.78% |
| Operating Margin | 43.54% | 13.32% |
| Debt to Equity | 0.01x | 0.87x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ANTHEM | BETA |
|---|---|---|
| Promoter Holding | 71.42%▼ 3.26 pp | 59.1%▼ 5.53 pp |
| FII Holding | 2.58%▲ 1.3 pp | 1.02%▼ 0.14 pp |
| DII Holding | 13.48%▲ 1.93 pp | 6.23%▲ 4.08 pp |
| Public Holding | 12.53%▲ 0.03 pp | 33.65%▲ 1.59 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ANTHEM BIOSCIENCES and BETA DRUGS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.